Vericel Stock Forecast, Price & News

-0.08 (-0.14 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume270,005 shs
Average Volume750,759 shs
Market Capitalization$2.67 billion
P/E Ratio719.84
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

Vericel logo

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.15 out of 5 stars

Medical Sector

1017th out of 2,096 stocks

Biological Products, Except Diagnostic Industry

138th out of 196 stocks

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vericel (NASDAQ:VCEL) Frequently Asked Questions

Is Vericel a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel
or view top-rated stocks.

What stocks does MarketBeat like better than Vericel?

Wall Street analysts have given Vericel a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vericel wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Vericel

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) announced its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.03. The biotechnology company earned $34.57 million during the quarter, compared to analyst estimates of $32.04 million. Vericel had a trailing twelve-month return on equity of 3.45% and a net margin of 3.24%. Vericel's revenue for the quarter was up 29.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.10) EPS.
View Vericel's earnings history

How has Vericel's stock price been impacted by Coronavirus?

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VCEL shares have increased by 376.7% and is now trading at $57.58.
View which stocks have been most impacted by COVID-19

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $165 million-$168 million, compared to the consensus revenue estimate of $162.53 million.

What price target have analysts set for VCEL?

8 brokers have issued 1 year target prices for Vericel's shares. Their forecasts range from $31.00 to $65.00. On average, they anticipate Vericel's stock price to reach $49.71 in the next twelve months. This suggests that the stock has a possible downside of 13.7%.
View analysts' price targets for Vericel
or view top-rated stocks among Wall Street analysts.

Who are Vericel's key executives?

Vericel's management team includes the following people:
  • Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 57, Pay $1.19M)
  • Mr. Michael Halpin, Chief Operating Officer (Age 60, Pay $585.43k)
  • Ms. Sandra Pennell, VP, Principal Accounting Officer & Controller (Age 41, Pay $276.92k)
  • Mr. Sean C. Flynn, VP, Gen. Counsel & Sec. (Age 47, Pay $502.69k)
  • Dr. Jonathan M. Hopper, Chief Medical Officer (Age 59, Pay $523.68k)
  • Mr. Joseph Anthony Mara Jr., CFO & Treasurer (Age 45)
  • Mr. Eric Burns, Exec. Director of Financial Planning and Analysis & Investor Relations
  • Ms. Heidi Hassen, VP of HR
  • Mr. Roland DeAngelis, Sr. VP of Commercial Operations

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel CEO Nick Colangelo on Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Vericel's key competitors?

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.75%), Brown Capital Management LLC (9.86%), Fred Alger Management LLC (5.88%), Waddell & Reed Financial Inc. (5.80%), Federated Hermes Inc. (3.32%) and Artisan Partners Limited Partnership (2.07%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton and Robert L Md Zerbe.
View institutional ownership trends for Vericel

Which institutional investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Kopp Family Office LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Goldman Sachs Group Inc., Pura Vida Investments LLC, Fort Washington Investment Advisors Inc. OH, Parkman Healthcare Partners LLC, and GW&K Investment Management LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, and Robert L Md Zerbe.
View insider buying and selling activity for Vericel
or view top insider-selling stocks.

Which institutional investors are buying Vericel stock?

VCEL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Fred Alger Management LLC, Brown Capital Management LLC, Artisan Partners Limited Partnership, Principal Financial Group Inc., Principal Financial Group Inc., Fisher Asset Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Vericel
or or view top insider-buying stocks.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $57.58.

How much money does Vericel make?

Vericel has a market capitalization of $2.67 billion and generates $124.18 million in revenue each year. The biotechnology company earns $3.04 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Vericel have?

Vericel employs 273 workers across the globe.

What is Vericel's official website?

The official website for Vericel is

Where are Vericel's headquarters?

Vericel is headquartered at 64 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.